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PURPOSE. Recent studies show that patients with Usher syndrome type 2 (USH2) have abnormal
cone structure and density in the central retina. This occurs in the presence of normal acuity,
opening the quest for additional sensitive functional measures of central cone function in USH.
We tested here whether focal macular cone electroretinogram (fERG) could be such a tool.
METHODS. This retrospective study of central cone function loss was based on data from 47
patients with USH2 from the Ophthalmology Department of the Policlinico Gemelli/Catholic
University in Rome. The analysis focused on the decrease of the fERG, obtained in response to
a 41-Hz sinusoidal modulation of a uniform field presented to the central 188, generated by red
light-emitting diodes (LEDs) and superimposed on an equiluminant steady adapting
background. fERG decrease was compared with the decrease of best-corrected visual acuity
and Goldmann kinetic perimetry V4E field.
RESULTS. fERG follow-up data document a severe and precocious loss of central cone function
in USH2 patients, preceding losses in other measures of cone function. fERG is already
reduced to 40% of control at the beginning of the second decade of life, and by 25 years of
age, all USH2 patients have fERGs less than 30% of control values.
CONCLUSIONS. fERG represents a sensitive tool to evaluate central cone function in USH2,
anticipating the decline of other central cone function measures, such as visual acuity and
Goldmann perimetry.
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Usher syndrome (USH) is an autosomal recessive group ofdiseases characterized by the association of retinitis
pigmentosa (RP)-like retinal degeneration with bilateral senso-
ry-neural hearing loss.1 On the basis of clinical studies2 and
genetic surveys,3–5 the prevalence of USH is estimated to be
between 1/10,000 and 1/50,000 people.
USH is the most common cause of deaf-blindness,6 and the
most frequent form of recessive RP, comprising 18% of all RPs.7
Three clinical subtypes are distinguishable, on the basis of the
degree and onset of hearing loss, the presence or absence of
vestibular abnormality, and the age of RP onset.8,9
Usher type 2 (USH2) is the most common of the three USH
subtypes, comprising 56% to 75% of USH patients.10–13 USH2 is
characterized by the lack of vestibular deficits and mild to
generally moderate degrees of congenital neurosensory hearing
loss; and, RP onset is usually in the second decade of life.9 In
USH2 patients, RP symptoms typically start with a concentric
visual field loss, whereas visual acuity remains well preserved
for a long time.14,15 Indeed, progression of visual field loss may
occur at a much faster rate than losses in visual acuity or cone-
mediated central light-adapted perimetry.14–16
Visual field testing, visual acuity, and central perimetry do not
directly assess retinal abnormalities, but rather global visual
performance, as the subject is required to respond to the
perceived stimuli. The use of objective tests specific for retinal
functions, such as foveal densitometry,17 multifocal electroretino-
gram (ERG),18 and focal macular ERGs (fERGs),19 shows early
central cone functional abnormalities in USH patients, as some
psychophysical studies do, showing early abnormal foveal spectral
sensitivity to short-wavelength light.20 Indeed, USH patients may
complain of central visual problems from the early stages,
reporting the need for high contrast visual stimuli for better
central vision, such as the need to shine a strong light on the
interlocutor’s lips to allow speech-reading (Falsini, unpublished).
Thus, although the concept of a peripheral to central
progression of the visual symptoms in USH disease is deeply
rooted, and likely corresponds to the relative severity of the
symptoms as perceived by patients, a more complex picture of
disease progression is very likely.
Anatomic studies also provide a complex picture of RP in
USH syndrome. Optical coherence tomography (OCT) in the
early stages of USH1 visual disease show the presence of a
transition zone between the relatively preserved central retina
and the more affected periphery.21 Typically, the ellipsoid zone
band in the central macular area of patients with USH1 is
reduced in extent only at the late stages of the disease, with an
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accompanying loss of the outer nuclear layer, and profound
losses in light-adapted, cone-mediated sensitivity in the central
and paracentral retinal regions. In USH2 however, abnormal
sensitivity has also been reported within the central region
encompassed by the intact ellipsoid zone in the early disease
stages.22 Confocal and nonconfocal split-detector adaptive
optics scanning light ophthalmoscopy (AOSLO) shows that
central and paracentral cones in USH may be altered in their
structure and probably in their waveguide function long before
visual acuity loss. Furthermore, it indicates that the number of
cones is significantly reduced in the central retina of patients
with USH, compared with control values.22
Taken together, these studies suggest that alongside severe
peripheral deficits, loss of both structure and function of the
central cone system in USH may characterize the early stages of
the disease, preceding losses in visual acuity and perimetric
sensitivity. Thus, identifying other sensitive functional mea-
sures of central retina cone function may certainly be helpful.
In the last 22 years, in the routine testing USH patients, we
have used a fast and noninvasive measure of central cone
function, the fERG. The fERG is obtained in response to the 41-
Hz sinusoidal modulation of a uniform field presented to the
central 188, generated by red light-emitting diodes (LEDs) and
superimposed on an equiluminant steady adapting background.
The fERG first harmonic correlates with perimetric sensitivity in
the same retinal region.19 In previous studies, we used fERG to
estimate the rate of central cone function decay in different
subtypes of RP,23 and in patients with cone dystrophy.24,25
Here, in a retrospective study, we present the evaluation of
central cone function by f ERG in a cohort of 47 patients with
USH2. Rather than focusing on the relative decay rate, as we
did in the past,23 we evaluated the absolute values of fERG
measures and their decrease with age, comparing such
decrease with changes in visual acuity and Goldmann kinetic
perimetry V4e. The results show that fERG documents a severe
and precocious loss of central cone function in patients with
USH2, anticipating losses in other measures of cone function.
METHODS
Patients
Forty-seven subjects (aged 12–75 years) affected by USH2 were
included in the study. Patients were clinically followed at the
Institute of Ophthalmology, Visual Electrophysiology Service at
Fondazione Policlinico Gemelli/Universita` Cattolica del S.
Cuore. With one exception, all patients were from central
and southern Italy (Supplementary Fig. S1).
A detailed medical and family history was obtained from the
patient and/or their parents. This included information
regarding age of diagnosis of hearing loss, nature of hearing
loss, age of perceived night blindness, age of RP diagnosis as
well as information regarding motor development (age at
which the patient first sat and walked, as well as whether and
when the patient learned to use a bicycle, a discriminating
criterion for vestibular integrity).
The diagnosis of USH2 was based on the lack of vestibular
deficits, the presence of a mild to generally moderate degree of
congenital neurosensory hearing loss, and RP. Audiometric
evaluations were available for most patients and showed
bilateral sensory hearing loss with a down-sloping configura-
tion.26 RP was diagnosed on the basis of a history of night-
blindness, typical retinal pigmentary changes, subnormal or
undetectable full-field electroretinographic amplitudes, and
progressive peripheral visual field loss.
Patients had a known inheritance pattern, and 23 of 47
patients also had identified genetic USH2a variants. Exclusion
criteria were the presence of severe ocular media opacities, or
concomitant ocular (e.g., glaucoma, amblyopia) or systemic
diseases. The demographic data for individual patients are
reported in Table 1. Table 2 provides the variant details for the
23 patients with identified genetic variants.
Informed consent to participate in the study was obtained
from all patients and control subjects, or their parents, after the
aims and modalities of the investigation had been fully
explained. The study followed the tenets of the Declaration
of Helsinki and was approved by the Ethics Committee of the
institution.
TABLE 1. Demographic Data of the USH2 Cohort Analyzed
Pt Number Sex Age, First Visit Follow-Up, y N Visits
1 f 27 4 4
2 f 20 1
3 m 50 10 7
4 f 35 1
5 m 29 2 3
6 m 12 9 7
7 f 33 1
8 m 42 1
9 f 69 1
10 f 59 2 3
11 m 21 5 4
12 f 58 1 2
13 m 43 1
14 f 55 1 2
15 f 49 1 2
16 m 33 1
17 m 18 5 6
18 f 31 2 3
19 m 14 1
20 m 48 1 2
21* f 53 22 18
22 f 21 1
23 f 27 1
24 f 53 1
25 m 21 1
26 m 32 14 6
27 f 69 5 3
28 f 24 7 3
29 m 17 8 8
30 f 51 9 10
31 m 23 16 14
32† f 47 5 4
33† m 37 7 4
34 m 29 2 3
35 m 39 1 2
36‡ f 14 5 3
37‡ m 22 22 14
38 f 32 5 4
39 f 48 1
40 m 15 18 13
41 m 56 2 2
42* m 60 4 5
43 f 36 1
44 m 37 1
45 m 62 3 4
46 f 45 13 8
47 f 55 8 7
f, female; m, male; Pt, patient.
* Sibling pairs.
† Sibling pairs.
‡ Sibling pairs.
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Molecular Genetic Analysis
In-solution target enrichment (‘‘Nextera Rapid Capture Enrich-
ment’’) on the Illumina platform (Illumina, San Diego, CA, USA)
was performed to sequence all coding exons and flanking
exon/intron boundaries of the genes known to be associated
with USH2.27 The raw read data, in fastq format, were analyzed
to generate the list of sequence variants using an in-house
pipeline, as previously described.28
Measures of Ocular Function and
Electroretinography
For each patient, a full, general, and ophthalmologic examina-
tion (including detailed family history, anterior segment
biomicroscopy, corrected visual acuity, direct and indirect
ophthalmoscopy, IOP measurement, and flash ERGs recorded
according to International Society for Clinical Electrophysiol-
ogy of Vision [ISCEV] standard protocols) was performed at
baseline. Best-corrected visual acuity (BCVA) was obtained
with a standardized, projected Snellen chart. Kinetic visual
fields were measured for the V4e white test light of the
Goldmann perimeter against the standard background of 31.5
apostilbs.
Cone-mediated fERG was recorded from the central 188
region using a uniform red field stimulus superimposed on an
equiluminant steady adapting background, used to minimize
stray-light modulation. The stimulus was generated by a
circular array of eight red LEDs (k maximum 660 nm, mean
luminance 93 cd/m2) presented on the rear of a Ganzfeld bowl
(white-adapting background, luminance: 40 cd/m2). A diffusing
filter in front of the LED array made it appear as a circle of
uniform red light. fERGs were recorded in response to the
sinusoidal 95% luminance modulation of the central red field.
The flickering frequency was 41 Hz. This apparatus has been
the same throughout the years, with periodic controls of LED
TABLE 2. Patient Subset With Identified Genetic Variants
Pt Number Sex
Allele
State
uSH2A Variants (NM_206933.2)
refSNP MAF
Variant
Interpretation t
Nucleotide
Change
Amino Acid
Change
8 M hom c.908G>A p.(Arg303His) rs371777049 T¼0.00005/6 (ExAC) Pathogenic
9 F het c.2299del p.(Glu767serfs*21) Pathogenic
het c.4046del p.(ser1349Phefs*17) Pathogenic
10 F hom c.2810 2993del p.(Gly937Aspfs*13) Pathogenic
12 F hom c.9815C>T p.(Pro3272Leu) A¼3.308e-05/4 (ExAC) Likely Pathogenic
13 M het c.7068T>G p.(Asn2356Lys) rs200038092 C¼0.0008/95 (ExAC) vuS
het c.14091del p.(Phe4697fs) Pathogenic
14 F het c.2209C>T p.(Arg737*) rs111033334 A¼0.000008/1 (ExAC) Pathogenic
het c.13447G>C p.(Gly4483Arg) G¼8.245e-06 /1 (ExAC) vus
M het c.15199del p.(lle5067serfs*23) Pathogenic
19 het c.10712C>T p.(Thr3571Met) rs202175091 A¼0.00002/2 (ExAC) Likely Pathogenic
20 M het c.990 991del p.(Asn330Lysfs*8) Pathogenic
het c.10712C>T p.(Thr3571Met) rs202175091 A¼0.00002/2 (ExAC) Likely Pathogenic
21 F het c.2276G>T p.(Cys759Phe) rs80338902 A¼0.0008/95 (ExAC) Pathogenic
het c.3215T>G p.(Leu1072Arg) vus
22 F het c.13130C>A p.(ser4377*) rs111033385 T¼0.000008/1 (ExAC) Pathogenic
het c.653T>A p.(val218Glu) rs397518026 T¼0.00004/5 (ExAC) Likely Pathogenic
23 F hom c.9815C>T p.(Pro3272Leu) A¼3.308e-05/4 (ExAC) Likely Pathogenic
25 M hom c.14248C>T p.(Gln4750*) rs727504867 Pathogenic
26 M het c.802G>A p.(Gly268Arg) rs111033280 T¼0.000008/1 (ExAC) vuS
het c.10437G>T p.(Trp3479Cys) vus
28 F het c.(1644þ1 1645-1)
(2293þ1 2294-1)dup
Pathogenic
het c.12067-2A>G rs397517978 C¼0.00007/8 (ExAC) Pathogenic
31 M het c.8584C>T p.(Gln2862*) Pathogenic
het c.13018G>C p.(Gly4340Arg) vus
34 M hom c.10699del p.(Leu3567*) Pathogenic
35 M het c.5959T>A p.(Tyr1987Asn) rs747652397 T¼0.00002/3 (ExAC) vus
het c.10451G>A p.(Arg3484Gln) rs771999994 T¼0.00008/10 (ExAC) vus
37 M het c.2299del p.(Glu767serfs*21) rs80338903 del G¼0.0008/96 (ExAC) Pathogenic
het c.4714C>T p.(Leu1572Phe) rs111033333 A¼0.0008/95 (ExAC) Likely Benign
40 M hom c.12006C>A p.(Tyr4002*) Pathogenic
M het c.2276G>T p.(Cys759Phe) rs80338902 A¼0.0008/95 (ExAC) Pathogenic
41 het c.14286C>A p.(Asn4762Lys) rs750368946 A¼0.00002/2 (ExAC) vus
43 F het c.1055C>T p.(Thr352lle) Likely Pathogenic
het c.10712C>T p.(Thr3571Met) rs202175091 A¼0.00002/2 (ExAC) Likely Pathogenic
44 M het c.12381 12382del p.(Tyr4128Hisfs*24) Pathogenic
het c.2299del p.(Glu767serfs*21) Pathogenic
46 F hom c.5221T>C p.(ser1741Pro) vus
Bold indicates ClinVar last evaluation; normal, classified in this study according to the criteria by the American College of Medical Genetics and
Genomics Standards and Guidelines.44 Het, heterozygous; Hom, homozygous; MAF, minor allele frequency; VuS, variant of uncertain significance.
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and background intensity. Patients fixated monocularly at a
0.258 central fixation mark, under the constant monitoring of
an external observer. Pupils were pharmacologically (1%
tropicamide and 2.5% phenylephrine hydrochloride) dilated
to a diameter of 8 mm, and all subjects underwent a
preadaptation period of 20 minutes to the stimulus mean
illuminance. fERGs were recorded by an Ag-AgCl electrode
taped on the skin over the lower eyelid. A similar electrode,
placed over the eyelid of the contralateral-patched eye, was
used as reference (interocular recording). fERG signals were
amplified (100,000-fold), bandpass filtered between 1 and 100
Hz (6 decibels/octave [dB/oct]), and averaged (12-bit resolu-
tion, 2-kHz sampling rate, 200–600 repetitions in 2–6 blocks).
Off-line discrete Fourier analysis quantified the peak-to-peak
amplitude and phase lag of the response fundamental
harmonic (first harmonic) at 41 Hz.
Data Acquisition and Analysis
For each patient, fERG measurements were obtained for each
eye, with the routine testing sequence of right eye–left eye–left
eye–right eye. The fERG value for each eye was the average of
its two recordings. For each patient, we determined the eye
with better fERG at the first visit and followed the results for
this eye for all the measurements we analyzed.
To minimize nonnormality, quantitative analyses used the
logMAR for visual acuity fractions,29 and the first harmonic
peak-to-peak amplitude as a measure of the fERG amplitude.30
All data analysis and plots were made using OriginPro 2015
(OriginLab Corporation, Northampton, MA, USA).
Goldmann Area Measure. Kinetic Goldmann visual field
maps were scanned as high-resolution TIFF images. These
images where then analyzed with Metamorph Offline (ver 5.0;
Universal Imaging Corp., West Chester, PA, USA), a quantitative
image analysis software. Briefly, for each field, the length of the
908 to 908 horizontal axis and the 708 to 708 vertical axis were
measured with the line tool for calibration. The Goldmann V4e
field map was then traced with the area tool to obtain its area
in pixels. This was then converted into degrees squared using
the calibration obtained with the horizontal and vertical axis
measurements. Area values were entered into a log file
together with patient and time data. The V4e isopter was
selected because it was available for all the patients and has
been used in many previous studies.14–16,31
Cross-Sectional Time-Course Curves. Cross-sectional
time-course curves were obtained by assigning each patient
data to the appropriate age bin (selected binning covered the
10- to 70-year span, with a 5-year bin size for fERG and a 10-
year bin size for BCVA and Goldmann V4e). For patients with
more than one measure within an age bin, the average value for
the bin was computed, so that each patient contributed only
one value to each age bin. The mean value, SD, and number of
contributing patients were then computed for each age bin.
The same procedure was followed to obtain the cross-sectional
time-course curve for fERG for control subjects.
The mean logMAR for control subjects was by definition 0
(corresponding to a 20/20 BCVA), with 0 SD. Data for control
Goldmann V4e were derived from 20 eyes of 10 age-matched
healthy subjects. The range of these control data is in
agreement with previous studies.14,15
The small number of control subjects for age group
prevented us from estimating the time course of the fifth
percentile with age. However, considering that fERG in control
subjects decreased 25% over the entire age span analyzed, we
estimated an average fifth percentile of fERG in control
subjects by pooling together all data, irrespective of age.
Estimated Average Annual Rate of Decline for fERG.
The average annual rate of decline for fERG within the 10 to 25
years age range was estimated by fitting the cross-sectional
fERG curve with an exponential decline, as in previous
studies.29
Plot of USH2 Data as Percentage of Control Data. To
plot USH2 patient data as percentage of healthy control data,
we expressed the cross-sectional mean and SD as percentages
of the control subject average value. In the case of fERG and
Goldmann V4e area, the range between 0 and the mean value
for control subjects was considered to be 0% to 100%
percentage range (100% ¼ control mean value, 0% ¼ 0). In
the case of logMAR, a logMAR equal to 0 (BCVA ¼ 20/20
decimal) was considered ¼ 100% of normal control, and a
logMAR of 2 (BCVA ¼ 2/200 decimal) was considered ¼ 0%.
Statistical Analysis
Data are presented as mean 6 SD, unless otherwise specified.
Statistical analysis was performed using Prism 6.0 (GraphPad
Software, Inc., La Jolla, CA, USA).
RESULTS
This retrospective study is based on data from 47 patients with
a clinical diagnosis of USH2. All patients were clinically
followed at the Ophthalmology Department of the Catholic
University in Rome. The cohort comprised 24 females and 23
males. Mean age at first visit was 37.6 years (SD 15.5, minimum
12, maximum 69, oldest at the last visit, 75 years).
For 15 patients, only fERG recordings from one visit (first
visit) were available. The remaining 32 patients (17 males, 15
females; average age at first visit 38.8 years, SD 16.6, median
38, minimum 12, maximum 69 years) had an average fERG
follow-up of 6.8 years (SD 6.0, median 5, minimum 1 maximum
22 years, see Table 1). Data were acquired in 253 visits,
spanning the years 1995 to 2017.
fERG Amplitude Versus Age
Typical fERG recordings from a healthy control subject and
two USH2 patients are shown in Supplementary Figure S2.
Individual fERG amplitude data plotted as a function of age
are shown in Figure 1A for 47 USH2 patients (1 eye per
patient; closed circles) and 62 age-matched control subjects
(open diamonds, age range 12–72 years, data from 101 eyes).
Lines connect longitudinal data from individual patients. The
cross-sectional averages of the same data computed pooling
together data in bins of 5 years (see Methods) are shown in
Figure 1B. As already reported, reliable fERGs can be
recorded only at the beginning of the second decade of
life.23 Examples of individual data recorded from nine
patients with long-term fERG follow-up are shown in Figure
2.
fERG responses showed some short-term variability; how-
ever, a clear trend toward a progressive decline with age was
evident. Intervisit variability (Supplementary Fig. S3) was
within the range reported in RP.23
In general, fERG responses in USH2 patients were
considerably lower than in age-matched healthy control
subjects already at the beginning of the second decade of life.
By this time, the response was within 5% of healthy control
subjects in only one patient, and the average value was 40% of
control values. By 25 years of age, all USH2 patients had fERGs
below 0.8 uV, (i.e., 30% of control values at this age). The
estimated average annual decrease in the 10 to 25 years of age
range was 5%. Thus, the two main peculiar features of fERG in
USH2 patients are a precocious decline with respect to normal
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and a very narrow time window within which most of the
decline occurs.
fERG Decline Compared With BCVA and Goldmann
V4e Area Decline With Age
The time course of fERG amplitude decline is compared in
Figure 3 with that of BCVA (plotted as logMAR) and Goldmann
V4e visual field area. For each patient, the same eye is analyzed
for all three measures. Dots represent individual data. Lines
connect follow-up data for individual patients. fERG data for
the first visit were available for 47 USH2 patients. Within this
cohort, BCVA measures were available for 46 patients, and
Goldmann V4e data were available for 42 patients. Follow-up
data were available for 32 (fERG), 36 (BCVA), and 20
(Goldmann V4e) patients. The thick black line and the gray
lines are the cross-sectional average versus age for patients and
control subjects, respectively.
As already reported in previous studies,14,15 both BCVA
value and Goldmann V4e visual field are normal until at least
the end of the second decade of life, both declining thereafter,
with a different onset of decline from patient to patient.
Thus, the BCVA and Goldman visual field time courses are
profoundly different from what observed for fERG, which is
already less than half the normal values at the beginning of the
second decade of life, with little further loss after 25 years of
age.
These different time courses are shown in Figure 4 in terms
of cross-sectional averages, expressed as percentage of control
values, versus age.
This comparison further emphasizes the precocity of fERG
decline and the steepness of its decline. On average, patient
fERG is already down to 40% of that of control subjects by the
beginning of the second decade of life, whereas BCVA cross-
sectional data remain above 40% of those of control subjects,
even in the sixth decade of life, and Goldman V4e cross-
sectional area data go below 40% of that of controls only when
patients are well into their fourth decade of life.
USH2 Patients With USH2A Identified Genetic
Variants
Only a fraction of the patients analyzed in this study had
undergone genotyping analysis (Table 2). When analysis was
restricted only to patients with identified genetic variants, the
same pattern of results as for the total patient sample was
evident: a rapid and stereotyped decline of fERG with age
(Supplementary Fig. S4).
FIGURE 1. fERG amplitude versus age in USH2 patients and control subjects. (A) USH2 data (black symbols) are from 47 patients. Longitudinal data
from individual patients are connected by lines. Control data (open diamonds) are from 62 subjects. The dotted line represent the fifth percentile of
control. (B) Cross-sectional average of data in (A) averaged over 5-year age groups. Symbols as in (A). Numbers within the symbols indicate the
number of subjects contributing to the age group average. Each patient contributes a maximum of one value (the average within the age group) to
each age-group mean.
FIGURE 2. (A, B) Examples of individual fERG follow-up with age. In each panel, different symbols refer to different patients. The gray lines are the
cross-sectional average over the entire patient cohort. Data are presented in two panels for clarity. Labels identify patients according to their listing
in Table 1.
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DISCUSSION
We have used fERG for more than 20 years to monitor the
function of cones in the central part of normal and diseased
retinas.23–25
The present retrospective analysis of fERG responses in
USH2 patients showed that fERG amplitude is already
significantly (40%) reduced with respect to control subjects
at the beginning of the second decade of life, when visual
acuity and Goldmann visual field are still normal. Moreover,
fERG rapidly declines, reaching 25% of that of control subjects
by approximately 25 years of age. A slow decline follows, soon
reaching a floor level.
In other words, fERG is abnormal well in advance of other
cone-related visual tests, such as visual acuity and Goldmann
kinetic visual field, and most of the fERG decline is completed
by 25 years of age.
Early Central Cone Deficits
These findings may have important implications for the
pathophysiology of retinal dysfunction associated with USH2.
Indeed, fERG data show that the central and paracentral (i.e.,
the 98 eccentricity from the fovea tested with fERG) cone
system is compromised early in the disease process, contrary
to what visual acuity would suggest.
The present results may seem at odds with the view that RP
in USH is a disease that affects central cone function late in life.
This view reflects the order in which a patient reports
complaints about visual function, which starts from night
blindness and proceed to visual field restriction and eventually
visual acuity loss. Yet, central cone deficits can be detected
early in life, and may represent an additional burden for
patients. On a subjective basis, USH2 patients report the early
need for high-contrast central stimuli to optimize vision-based
performances, such as speech reading (Falsini, unpublished).
Psychophysical studies have shown abnormal foveal spec-
tral sensitivity for short wavelengths in USH patients,20 and
abnormal foveal, focal macular, and multifocal ERGs have been
reported in the early stages of RP and USH.18,19,23,29,32,33
Furthermore, anatomic studies using adaptive optics show
structural abnormalities in central cones in USH patients.
Despite the presence of normal ellipsoid and interdigitation
zones detectable with OCT, foveal and parafoveal cone
densities were significantly reduced with respect to control
data when analyzed with AOSLO.22 These changes were mainly
due to the prevalence of cones with nonwave-guiding
characteristics. The abnormal cones had intact inner segments,
leading to the conclusion that foveal and parafoveal cone
FIGURE 3. fERG, BCVA, and Goldmann V4e visual field versus age. In each plot, gray symbols represent individual data (longitudinal data from
individual patients are connected by lines). The thick black lines represent the cross-sectional average versus age. The gray horizontal lines
indicate the average values for control subjects computed over 10-year periods. fERG amplitude, logMAR, and Goldmann V4e area are presented for
the same eye. fERG data are from 47 USH2 patients, of whom BCVA was available for 46 and Goldmann V4e data for 42 patients. Thirty-two patients
had follow-up data for fERG, 20 for Goldmann V4e, and 36 for BCVA.
FIGURE 4. (A) fERG, (B) BCVA, (C) and Goldmann V4e visual field versus age expressed as percentage of control values. In each plot, the black line
represents the cross-sectional average of the variable, whereas the gray area indicates its SD. The number within the symbols indicate the number
of patients/control subjects contributing to the age-group average. The dotted lines represent the fifth percentile of control. For fERG and Goldman
V4e, 100% is the average of control data, 0% the zero value. The logMAR range considered is from 0 (100%) to 2 (0%).
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structure and density may be abnormal long before visual
acuity decreases.
Indeed, cone density can be reduced by nearly 40% before
visual acuity goes below 8/10 (logMAR 0.097),22 and histo-
pathologic studies show that RP patients may have relatively
high acuity ante mortem (‡8/10), and yet retain a single rim of
cones in the fovea.34,35
The early and rapid fERG decline we found could represent
an electrophysiologic correlate of the early abnormalities in
structure and density found for central cones in USH. fERG
amplitude loss could reflect a reduction in the number of cone
signal generators within the central 98 from which fERG
response is recorded, but also a reduced quantum catching
ability of the same cells, suggesting that fERG could reflect a
stage of dysfunction that may precede cell loss.
Estimates of Rate of Decline in Central Cone
Function Based on ERG Studies
The rate of decline of central cone function in RP patients has
been evaluated in several previous studies by the use of focal or
multifocal ERGs. This led to estimated average annual rates of
decline ranging between a 5% and 10%. In a cohort of RP
patients, Berson et al.29 found an average annual rate of fERG
amplitude decline of 5.2% using a 48, 42-Hz stimuli. Holopigian
et al.,33 using a 98, 40-Hz stimuli, reported an annual rate of
decline of 10%. An average annual rate of decline of 6% to 10%
has been found for multifocal ERG amplitudes in a cohort of RP
patients including two USH patients.32 Finally, we previously
reported a 6% average annual decline for fERG (188, 41 Hz)
amplitude in 14 USH2 patients.23
The average annual decline of central cone function
estimated on the basis of fERG in the present study is 5%, in
line with previous results. The present study also shows that
fERG, differently from BCVA and Goldmann visual field,
decreases in a stereotyped way with age, independently of
the individual age of onset of visual deficits.
fERG Decline Compared With BCVA Goldmann
Visual Field Decline
In the present study, both cross-sectional and longitudinal fERG
recordings indicate that central cone function is abnormal
much earlier than visual acuity in USH2 patients. This indicates
that assessment of central visual function should take into
account that visual acuity may underestimate the abnormalities
in central retinal cone function. Indeed, while we see an
average annual fERG decrease of approximately 5%, and initial
fERG values already down to 40% of normal at the beginning of
the second decade of life, BCVA is initially normal in USH2
patients and declines at a much slower rate.
This is in line with previous studies on RP patient cohorts,
showing a 2% to 3% average annual rate of decline, once BCVA
begins to decrease.33,36,37
The finding that fERG losses precede BCVA decline by many
years in USH2 patients is in accordance with a previous study
on cone–rod dystrophies where we found that BCVA loss
invariably followed fERG loss, with a variable delay of years.24
We can only speculate as to why fERG is more sensitive than
BCVA to central cone deficits. fERG is an electroretinographic
measure obtained as an integrated response of the whole cone
system in the central 98 of the retina.30 Conversely, BCVA is a
psychophysical measure to which only the central retinal
region with the highest cone density contributes. This region
has been shown to be the most resistant to cone degeneration
in human retinal dystrophies,38 as well as in animal models of
retinal dystrophies.39
The average annual rate of Goldman V4e decline in USH2
patients has been estimated to be approximately 15% to
18%,14,15 in line with previous results in RP cohorts.29,33,40–42
These annual rates of change are higher than what we found
for fERG, but fERG starts declining much earlier than
Goldmann V4e area in USH2 patients, and depends on age
rather than on age of onset of visual deficits, as does Goldman
perimetry decline.15 For these reasons, fERG decline antici-
pates Goldmann V4e decline by many years.
One could object that the V4e isopter is not likely to be a
sensitive measure of change in central cone function. However,
the Goldman III4e isopter, which probably more accurately
reflects central cone function than the V4e isopter, did not
show any correlation with fERG (data not shown). A possible
explanation for this lack of correlation is that fERG is a direct
measure of retinal function, whereas Goldman visual field
measures require subjective responses, and thus also involve
post retinal processing.
fERG Limitations
Like all techniques, fERG has limitations. In particular, fERG
provides information about losses in the central macular
region; but, unlike multifocal ERG, it does not provide
topographic information. In addition, as we showed here, its
precocious decline makes it most useful in an early age
window, whereas, with disease progression, other measures,
such as static perimetry, autofluorescence, and/or analysis of
the extent of the intact ellipsoid zone band as a marker of
usable visual field, may be more useful to follow disease
progression.
Clinical Implications
In the present study, we found no apparent relationship
between fERG decline and either BCVA or Goldman V4e
decline. Indeed, whereas the onset of BCVA and Goldmann
field decay varies from patient to patient,14,15,36 fERG decline
occurs in a restricted age window, with 75% of the loss
occurring by 25 years of age in all patients.
In this respect, BCVA and Goldmann measurements appear
more valuable than fERG for patients, because with these
measures clinicians can provide indications of rates of decline
to the patient, once the disease has established its
course.14–16,31,36,43
Conversely, fERG decline does not seem to depend on
disease onset, but rather it follows an almost stereotyped
course with age. It can still be used to estimate the average rate
of central cone function decay,23 but its restricted and almost
invariant age window of decline makes it most of all a hallmark
of the disease. Yet, finding an indicator of early central cone
dysfunction may have important implications for any attempt
toward therapeutic approaches, being for instance a possible
early readout of the intervention efficacy.
In conclusion, this study shows the usefulness of fERG to
monitor central cone decline in USH2 patients, particularly in
the early stages of the disease. This is in line with a number of
previously published studies showing the usefulness of focal
ERG and multifocal ERG in detecting central visual deficits in
RP patients.
Acknowledgments
The authors thank Nicoletta Berardi and Alessandro Sale for critical
reading of the manuscript.
Supported by grants from Rare Partners onlus (BF; Milan, Italy), ex
60% MIUR (BF; Rome, Italy), and Fondazione Roma (LGR; Rome,
Italy).
Central Cone Function in Usher 2 Syndrome IOVS j August 2018 j Vol. 59 j No. 10 j 3833
Downloaded from iovs.arvojournals.org on 07/05/2019
Disclosure: L. Galli-Resta, None; G. Placidi, None; F. Campa-
gna, None; L. Ziccardi, None; M. Piccardi, None; A. Minnella,
None; E. Abed, None; S. Iovine, None; P. Maltese, None; M.
Bertelli, None; B. Falsini, None
References
1. Fishman GA, Kumar A, Joseph ME, Torok N, Anderson RJ.
Usher’s syndrome. Ophthalmic and neuro-otologic findings
suggesting genetic heterogeneity. Arch Ophthalmol. 1983;
101:1367–1374.
2. Keats BJ, Corey DP. The usher syndromes. Am J Med Genet.
1999;89:158–166.
3. Mets MB, Young NM, Pass A, Lasky JB. Early diagnosis of Usher
syndrome in children. Trans Am Ophthalmol Soc. 2000;98:
237–242; discussion 243–245.
4. Loundon N, Marlin S, Busquet D, et al. Usher syndrome and
cochlear implantation. Otol Neurotol. 2003;24:216–221.
5. Kimberling WJ, Hildebrand MS, Shearer AE, et al. Frequency
of Usher syndrome in two pediatric populations: implications
for genetic screening of deaf and hard of hearing children.
Genet Med. 2010;12:512–516.
6. Petit C. Usher syndrome: from genetics to pathogenesis.
Annu Rev Genomics Hum Genet. 2001;2:271–297.
7. Boughman JA, Vernon M, Shaver KA. Usher syndrome:
definition and estimate of prevalence from two high-risk
populations. J Chronic Dis. 1983;36:595–603.
8. Davenport SLH, Omenn GS. The heterogeneity of Usher
syndrome. In: Littlefield JW, de Grouchy J, Ebling FJG.
Proceedings of the 5th International Conference on Birth
Defects, Montreal, Canada, 21-27 August, 1997. Amsterdam:
Excerpta Medica; 1977.
9. Smith RJ, Berlin CI, Hejtmancik JF, et al. Clinical diagnosis of
the Usher syndromes. Usher Syndrome Consortium. Am J
Med Genet. 1994;50:32–38.
10. Grondahl J. Estimation of prognosis and prevalence of retinitis
pigmentosa and Usher syndrome in Norway. Clin Genet.
1987;31:255–264.
11. Hope CI, Bundey S, Proops D, Fielder AR. Usher syndrome in
the city of Birmingham–prevalence and clinical classification.
Br J Ophthalmol. 1997;81:46–53.
12. Rosenberg T, Haim M, Hauch AM, Parving A. The prevalence
of Usher syndrome and other retinal dystrophy-hearing
impairment associations. Clin Genet. 1997;51:314–321.
13. Spandau UH, Rohrschneider K. Prevalence and geographical
distribution of Usher syndrome in Germany. Graefes Arch
Clin Exp Ophthalmol. 2002;240:495–498.
14. Fishman GA, Bozbeyoglu S, Massof RW, Kimberling W. Natural
course of visual field loss in patients with Type 2 Usher
syndrome. Retina. 2007;27:601–608.
15. Iannaccone A, Kritchevsky SB, Ciccarelli ML, et al. Kinetics of
visual field loss in Usher syndrome Type II. Invest Ophthal-
mol Vis Sci. 2004;45:784–792.
16. Edwards A, Fishman GA, Anderson RJ, Grover S, Derlacki DJ.
Visual acuity and visual field impairment in Usher syndrome.
Arch Ophthalmol. 1998;116:165–168.
17. van Meel GJ, van Norren D. Foveal densitometry in retinitis
pigmentosa. Invest Ophthalmol Vis Sci. 1983;24:1123–1130.
18. Biersdorf WR. The clinical utility of the foveal electroretino-
gram: a review. Doc Ophthalmol. 1989;73:313–325.
19. Iarossi G, Falsini B, Piccardi M. Regional cone dysfunction in
retinitis pigmentosa evaluated by flicker ERGs: relationship
with perimetric sensitivity losses. Invest Ophthalmol Vis Sci.
2003;44:866–874.
20. Alexander KR, Hutman LP, Fishman GA. Dark-adapted foveal
thresholds and visual acuity in retinitis pigmentosa. Arch
Ophthalmol. 1986;104:390–394.
21. Sumaroka A, Matsui R, Cideciyan AV, et al. Outer retinal
changes including the ellipsoid zone band in Usher syndrome
1B due to MYO7A mutations. Invest Ophthalmol Vis Sci.
2016;57:OCT253–OCT261.
22. Sun LW, Johnson RD, Langlo CS, et al. Assessing photorecep-
tor structure in retinitis pigmentosa and Usher syndrome.
Invest Ophthalmol Vis Sci 2016;57:2428–2442.
23. Falsini B, Galli-Resta L, Fadda A, et al. Long-term decline of
central cone function in retinitis pigmentosa evaluated by
focal electroretinogram. Invest Ophthalmol Vis Sci. 2012;53:
7701–7709.
24. Galli-Resta L, Piccardi M, Ziccardi L, et al. Early detection of
central visual function decline in cone-rod dystrophy by the
use of macular focal cone electroretinogram. Invest Oph-
thalmol Vis Sci. 2013;54:6560–6569.
25. Galli-Resta L, Falsini B, Rossi G, et al. Bilateral symmetry of
visual function loss in cone-rod dystrophies. Invest Ophthal-
mol Vis Sci. 2016;57:3759–3768.
26. Kumar A, Fishman G, Torok N. Vestibular and auditory
function in Usher’s syndrome. Ann Otol Rhinol Laryngol.
1984;93:600–608.
27. Bonnet C, Riahi Z, Chantot-Bastaraud S, et al. An innovative
strategy for the molecular diagnosis of Usher syndrome
identifies causal biallelic mutations in 93% of European
patients. Eur J Hum Genet. 2016;24:1730–1738.
28. Maltese PE, Orlova N, Krasikova E, et al. Gene-targeted
analysis of clinically diagnosed long QT Russian families. Int
Heart J. 2017;58:81–87.
29. Berson EL, Sandberg MA, Rosner B, Birch DG, Hanson AH.
Natural course of retinitis pigmentosa over a three-year
interval. Am J Ophthalmol. 1985;99:240–251.
30. Falsini B, Iarossi G, Fadda A, et al. The fundamental and
second harmonic of the photopic flicker electroretinogram:
temporal frequency-dependent abnormalities in retinitis
pigmentosa. Clin Neurophysiol. 1999;110:1554–1562.
31. Testa F, Melillo P, Bonnet C, et al. Clinical presentation and
disease course of Usher Syndrome because of mutations in
Myo7a or Ush2a. Retina. 2017;37:1581–1590.
32. Nagy D, Schonfisch B, Zrenner E, Jagle H. Long-term follow-
up of retinitis pigmentosa patients with multifocal electro-
retinography. Invest Ophthalmol Vis Sci. 2008;49:4664–
4671.
33. Holopigian K, Greenstein V, Seiple W, Carr RE. Rates of
change differ among measures of visual function in patients
with retinitis pigmentosa. Ophthalmology. 1996;103:398–
405.
34. Kolb H, Gouras P. Electron microscopic observations of
human retinitis pigmentosa, dominantly inherited. Invest
Ophthalmol. 1974;13:487–498.
35. Milam AH, Li ZY, Fariss RN. Histopathology of the human
retina in retinitis pigmentosa. Prog Retin Eye Res. 1998;17:
175–205.
36. Sandberg MA, Rosner B, Weigel-DiFranco C, et al. Disease
course in patients with autosomal recessive retinitis pigmen-
tosa due to the USH2A gene. Invest Ophthalmol Vis Sci. 2008;
49:5532–5539.
37. Birch DG, Anderson JL, Fish GE. Yearly rates of rod and cone
functional loss in retinitis pigmentosa and cone-rod dystro-
phy. Ophthalmology. 1999;106:258–268.
38. Jacobson SG, Roman AJ, Aleman TS, et al. Normal central
retinal function and structure preserved in retinitis
pigmentosa. Invest Ophthalmol Vis Sci. 2010;51:1079–
1085.
39. Punzo C, Xiong W, Cepko CL. Loss of daylight vision in retinal
degeneration: are oxidative stress and metabolic dysregula-
tion to blame? J Biol Chem. 2012;287:1642–1648.
Central Cone Function in Usher 2 Syndrome IOVS j August 2018 j Vol. 59 j No. 10 j 3834
Downloaded from iovs.arvojournals.org on 07/05/2019
40. Madreperla SA, Palmer RW, Massof RW, Finkelstein D. Visual
acuity loss in retinitis pigmentosa. Relationship to visual field
loss. Arch Ophthalmol 1990;108:358–361.
41. Grover S, Fishman GA, Anderson RJ, Lindeman M. A
longitudinal study of visual function in carriers of X-linked
recessive retinitis pigmentosa. Ophthalmology. 2000;107:
386–396.
42. Massof RW, Dagnelie G, Benzschawel T, Palmer RW, Finkel-
stein D. First-order dynamics of visual field loss in retinitis
pigmentosa. Clin Vis Sci. 1990;5:1–26.
43. Piazza L, Fishman GA, Farber M, Derlacki D, Anderson RJ.
Visual acuity loss in patients with Usher’s syndrome. Arch
Ophthalmol. 1986;104:1336–1339.
44. Richards S, Aziz N, Bale S, et al; for the ACMG Laboratory
Quality Assurance Committee. Standards and guidelines for
the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics
and Genomics and the Association for Molecular Pathology.
Genet Med. 2015;17:405–424.
Central Cone Function in Usher 2 Syndrome IOVS j August 2018 j Vol. 59 j No. 10 j 3835
Downloaded from iovs.arvojournals.org on 07/05/2019
